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The management of streptococcal and enterococcal endocarditis has changed in recent years with the development of effec-
tive new regimens that are easier to administer, but resistance to commonly used antibiotics has appeared, especially among
enterococci. Beta-lactam antibiotics either alone or in combination are suitable for most patients with viridans streptococci
Streptococci bovis, and S. pneumoniae, but alternative regimens are necessary for special situations. Group B, C and G
streptococci respond best to the combination of a penicillin and an aminoglycoside.
Enterococci are relatively resistant to penicillins and cephalosporins and strains resistant to beta-lactams, glycopeptides
and aminoglycosides have become more common lately. Strategies are proposed dependent on the resistance of the
organisms, but it is recognized that medical failure is not uncommon and surgical removal of the infected valve may be the
only curative treatment.
Introduction
Streptococci account for approximately 50 to 60% of all
cases of infective endocarditis, most of which are caused by
viridans streptococci or Streptococcus bovis. Enterococci
account for approximately 10% of cases of streptococcal
endocarditis'1'. During the last few years, changes have
occurred that influence the treatment of this disease'21. New
regimens that are more convenient to administer have
been found to be effective, but resistance to commonly
used antibiotics have appeared, especially among entero-
cocci, that greatly compromise the success of treatment'31.
The purpose of this report is to review the present options
for the antibiotic therapy of streptococcal and enterococcal
endocarditis.
Viridans streptococci, Streptococcus bovis
Viridans streptococci are a heterogeneous group of
microorganisms which include a variety of strep-
tococcal species: Streptococcus sanguis, Streptococcus
mitis, Streptococcus salivarius, Streptococcus mutans,
Streptococcus oralis and others. Although Streptococcus
bovis is a non-enterococcal group D streptococcus, its pat-
tern of susceptibility to antibiotics is similar to that of viri-
dans streptococci. The vast majority of these streptococci
are highly sensitive to penicillin and other beta-lactam
antibiotics, with minimum inhibitory concentrations of
< 0-1 mg.l"1. However, a few strains have minimum
inhibitory concentrations to penicillin greater than 1
mg.1"1. Among 142 patients with streptococcal endocardi-
tis, Wilson and Geraci observed seven such strains'41. Some
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strains have minimum inhibitory concentrations to peni-
cillin greater than 0-5 mg.l~', and therapy should be the
same as that for enterococci'11.
Although there are reports of successful treatment of
streptococcal endocarditis with only a few million units of
penicillin administered for a period as short as 6 days'5', a
high percentage of cures can only be obtained with pro-
longed therapy with high doses of antibiotics or a combi-
nation of antibiotics. There are several options for anti-
biotic therapy, all of which have certain advantages and
disadvantages, and the selection of a specific regimen
should be individualized for each patient (Tables 1 and 2).
Beta-lactam therapy alone for 4 weeks
If a beta-lactam is used alone, it should be administered
for 4 weeks. In early clinical trials, penicillin at a dose of 14
to 16 million units per day and administered for 10 to 14
days still resulted in relapse rates of 15%, whereas the rate
for beta-lactam is only in the range of 1 to 2% when ther-
apy is given for 4 weeks'4'.
Aqueous crystalline penicillin G in doses of 10 to 20 mil-
lion units per day for 4 weeks is a classically recommended
regimen. However, recently, ceftriaxone sodium adminis-
tered at a once daily dose of 2 g has also been found to be
an effective and safe treatment of streptococcal endocardi-
tis'2-6'. In hospital, this agent may be more convenient to
administer than penicillin G, and some patients may be
able to be treated partially or entirely as outpatients. With
both of these agents, bacteriological cure can be expected
in approximately 99% of the patients'7'.
Beta-lactam for 2 weeks + aminoglycoside for 2 weeks
Because of evidence in-vitro and from animal models of
synergism between beta-lactams and aminoglycosides,
shorter courses of combined therapy have been tested.
Although older reports of the combination of penicillin
0195-668X/95/OB0075 + 05 $08.00/0 © 1995 The European Society of Cardiology
76 P. Francioli
Table 1 Therapeutic options in streptococcal endocarditis
(A) Viridans streptococci, .£ bovis (2 minimum inhibitory concentrations < 01 mg.1 '
1. Beta-lactam therapy alone X 4 weeks
2. Vancomycin or teicoplanin X 4 weeks
3. Beta-lactam x 2 weeks + aminoglycoside X 2 weeks
4. Combined parenteral and oral regimens
5. Outpatient therapy options
(B) Particular cases
Nutritionally deficient variants of viridans streptococci
Minimum inhibitory concentration > 01 mg.l"' < 0-5 mg.l"1
Duration of symptoms > 3 months
Extracardiac infection, mycotic aneurysm
1. Beta-lactam x 4 weeks + aminoglycoside X 2-4 weeks
2. Vancomycin x 4 weeks + aminoglycoside X 2-4 weeks
(C) £ pneumoniae, group A streptococci
1. Beta-lactam X 4 weeks
2. Vancomycin x 4 weeks
(D) Group B, C, G streptococci
1. Beta-lactam X 4 weeks + aminoglycoside X 2 weeks
2. Vancomycin x 4 weeks + aminogylcoside X 2 weeks
and streptomycin indicated failure rates in the range of 6 to
11%, more recent reports have shown excellent results,
with bacteriological cure rates as high as 99% in selected
cases'81. Recently, a 14-day course of ceftriaxone combined
with netilmicin, both administered as a single daily dose,
has been tested in a multicentre trial. Among 43 bacterio-
logically assessable cases, only one relapse occurred in a
case caused by Gemella morbillorum, a microorganism
which has been associated with an unusual course of endo-
carditis'9'. Obviously, the combined regimen of ceftriaxone
and netilmicin is much more convenient to administer than
penicillin plus streptomycin and it may also be less toxic1'1.
However, because of the limited experience of once-daily
administration of aminoglycoside in endocarditis in
humans, this cannot yet be recommended as a standard
treatment. Regarding efficacy, streptomycin and genta-
micin are probably equivalent'1'. Nowadays, gentamicin is
generally preferred because it is better tolerated when
administered intravenously and because serum levels can
easily be monitored (Table 3).
Unless clearly indicated (see below), regimens including
an aminoglycoside should probably not be used in patients
with impaired renal or auditory function, or in older
Table 2 Suggested daily dosages for the major antibiotics used in







6 X 2-3 million units
6 x 2 g
2g
2X15 mg.kg"' (> 60 min)
3 mg.kg-' (divided in 2-3 (1?) doses)
2 x 7-5 mg.kg-1 (60 min)
* Non-enterococcal streptococci only.
Table 3 Which aminoglycoside in streptococcal and enterococcal
endocarditis?
Published clinical experience SM > GM
Synergy in vitro and in animal models SM = GM
High level resistance in streptococci (rare) SM > > GM
High level resistance in enterococci SM > > GM
Tolerance to intravenous administration GM > SM
Monitoring GM > > SM
SM = streptomycin; GM = gentamicin.
patients'1-8-9'. In these patients, sole administration of a
beta-lactam for 4 weeks is preferred.
Vancomycin or teicoplanin for 4 weeks
In patients allergic to penicillin, ceftriaxone can be used
if hypersensitivity is not of the immediate-type. In any
patient with immediate-type hypersensitivity to penicillin
or other beta-lactams, vancomycin can be used for 4 weeks
at a dose of 15 mg.kg"1 every 12 h (administered intra-
venously in over an hour)'1'. Serum levels should be moni-
tored, especially in patients with renal dysfunction'9'.
However, there is limited published experience with this
agent for that indication. Teicoplanin, a glycopeptide with
a long half-life allowing once daily administration, has also
been used in viridans streptococcal endocarditis. However,
of 10 patients who completed a 4-week course of
teicoplanin (500 mg every 12 h on the first 2 days and then
10 mg.kg"1 every 24 h), nine were cured but one relapsed.
Moreover, among the 20 patients who entered the study,
five (25%) experienced drug fever which prompted inter-
ruption of treatment'10'. Thus, teicoplanin deserves further
investigation before it can be recommended as an alterna-
tive once-daily parenteral regimen for the treatment of
streptococcal endocarditis.
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Combined parenteral and oral regimens
Although oral therapy with high dose oral amoxicillin or
ampicillin plus probenecid has been successful in the treat-
ment of streptococcal endocarditis, it is not generally rec-
ommended because serum levels are lower and less
predictable than after parenteral administration1'1. More-
over, compliance may be a problem in some patients.
However, combined parenteral and oral regimens have
been successfully used in some countries161. Thus,
Stamboulian et al. successfully treated 15 patients with 14
days of ceftriaxone followed by 14 days of high-dose oral
amoxicillin. In these patients, serum bactericidal titres
above 1/8 was demonstrated while on oral treatment.
Options for outpatient therapy
Economic constraints have encouraged the treatment of
endocarditis in the home'111. This has been made feasible
with the use of once-daily administration of ceftriaxone. In
one study, among 55 patients treated for 4 weeks with this
agent, 23 could be discharged from hospital after less than
2 weeks and seven, who had to stay in hospital for the
entire course of treatment, only did so because of an inap-
propriate outpatient setting!21. In a study performed in
Argentina, seven out of 30 patients could be treated
entirely as outpatients and 27 received both inpatient and
outpatient treatment'61.
Obviously, outpatient therapy should only be considered
in the patient whose condition is stable and for whom med-
ical supervision can be maintained1"1, but treatment should
probably be initiated in hospital. Patients who are haemo-
dynamically unstable, who have large vegetations or other
echocardiographic findings associated with high rates of
complications, or who are suspected of distant metastatic
complications, should stay in the hospital.
Viridans streptococci: special situations
In several situations, a 4-week course of a cell-wall active
agent combined with an aminoglycoside for 2-4 weeks is
indicated11121. These situations include nutritionally defi-
cient variants of viridans streptococci, streptococci with a
minimum inhibitory concentration for penicillin greater
than 01 mg.r1 but less than 0-5 mg.l"1, patients with extra-
cardiac infection such as mycotic aneurysm, patients whose
symptoms have lasted more than 3 months, patients who
have experienced a relapse with the same organism and
patients who are receiving penicillin prophylaxis for
rheumatic fever. Some authorities also recommend such a
regimen for prosthetic valve endocarditis1121. In the pub-
lished experience1121, the cell-wall active agent most com-
monly used was penicillin G, but vancomycin has been
recommended as an alternative. However, there is no rea-
son why ceftriaxone or cefazolin would not work in these
situations. The choice of the aminoglycoside has been dis-
cussed above.
5. pneumon'iae, group A streptococci
Until recently, all strains of S. pneumoniae and group A
streptococci were highly sensitive to penicillin. For these
two microorganisms, penicillin G and vancomycin (as an
alternative in penicillin-allergic patients) have been rec-
ommended112'. Since these microorganisms are also
extremely sensitive to ceftriaxone, this agent can probably
also be used. However, due to the increasing incidence of
51 pneumon'iae resistant to penicillin in some parts of the
world, careful testing of susceptibility should always be
performed.
Group B, C, G streptococci
Group B streptococci are less sensitive to penicillin G
than are group A isolates. Synergy between penicillin and
an aminoglycoside has been demonstrated in-vitro against
non-tolerant as well as tolerant isolates and in animal mod-
els of endocarditis. Therefore, a combination of cell-wall
active agents combined with an aminoglycoside should be
considered in these patients1121. The same holds true for
group C and group G streptococci'121.
Enterococci
Enterococci are streptococci which belong to
Lancefield's group D. They include members of several dif-
ferent streptococcal species, such as Enterococcus faecalis,
Enterococcus faecium and Enterococcus durans. Treatment
of enterococcal endocarditis is complicated, because these
microorganisms are more resistant to penicillin G (median
minimum inhibitory concentration of 2 mg.l"1) and
to extended spectrum penicillins than most other
streptococci; they are also uniformally resistant to
cephalosporins131. In addition, cell-wall active antibiotics
are only bacteriostatic'11. Although enterococci are also
resistant to aminoglycoside antibiotics, the combination of
penicillin, ampicillin, or vancomycin with certain amino-
glycoside antibiotics has been found to exercise a synergis-
tic bactericidal effect on these bacteria, provided that they
do not display a high level of resistance1131. A few years ago,
the problem became much more complicated because of
the emergence of strains resistant to one or more of the fol-
lowing classes of antibiotics: beta-lactams, glycopeptides
and aminoglycosides (Table 4).
Regarding beta-lactams, the resistance can be caused
either by decreased affinity of penicillin-binding proteins
to the drug (intrinsic resistance) or to beta-lactamase pro-
duction13141. Recently, strains resistant to vancomycin
and/or teicoplanin have also been identified. The mecha-
nism of resistance has not yet been fully characterized, but
several phenotypes (Van A, Van B, Van C) ranging from a
low to a high-level of resistance, have been described1151.
The degree of resistance to aminoglycosides is highly
variable. A minimum inhibitory concentration greater than
or equal to 2000 mg.r1 is generally considered to be the
limit between a low and a high-level of resistance'1'.
Enterococci which are highly resistant to an aminoglyco-
side are not killed synergistically when this agent is com-
bined with a cell-wall active agent in-vitro or in
experimental models'1161. Resistance is due to the presence
of various enzymes which modify the structure of the
aminoglycoside13'. Since the enzymes involved in the resis-
tance to streptomycin and gentamicin are different, some
strains resistant to one of the aminoglycosides might be
susceptible to the other.
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Table 4 Enterococcv resistance (R) to antibiotics
Beta-lactams
(a) Intrinsic resistance (PBPs)
(b) Beta-lactamase (plasmids)
Glycopeptides
(a) Van C low level R to vancomycin susceptible to teicoplanin
(b) Van B intermediate level R to vancomycin
(c) Van A high level R to vancomycin resistant to teicoplanin
Aminoglycosides
(a) high level R to streptomycin low level R to gentamicin
(b) high level R to gentamicin low level R to streptomycin
(c) high level R to gentamicin high level R to streptomycin
R = resistance; PBP = penicillin binding protein.
A suggested strategy for the choice of treatment of en- Some strains resistant to vancomycin have retained sus-
terococcal endocarditis is outlined in Table 5. It should be ceptibility to teicoplanin131. If the strain is resistant to both
kept in mind that combined therapy is required for sue- beta-lactams and glycopeptides, a triple combination of
cessful treatment: treatment with penicillin alone has vancomycin, penicillin or ampicillin and aminoglycoside
resulted in relapse rates of 25% or more. The minimum can be tried, provided that the strain is not highly resistant
duration of treatment should be 4 weeks but many author- to the aminoglycoside'131. Hence, vancomycin has been
ities suggest 6 weeks'11. The first step is to choose a cell-wall shown to reduce the minimum inhibitory concentration to
active agent. If the strain is sensitive to ampicillin, this penicillin when used with other drugs,
agent should be chosen. Since low levels of beta-lactamase If the strain is not highly resistant to streptomycin or gen-
production might not be detected by routine susceptibility tamicin, the synergistic effect provided by these two agents
testing, beta-lactamase production should be looked for if is similar11'. Other aminoglycosides cannot routinely be sub-
ampicillin is used'ul4'. In some experimental studies, con- stituted. If the strain is highly resistant to gentamicin, strep-
tinuous intravenous infusion was found to be more effec- tomycin should be tested. If high levels of resistance are
tive than intermittent dosing'16'. If a strain produces present for both agents, the synergistic effect is lost and the
beta-lactamase, amoxicillin/clavulanate can probably be aminoglycoside should therefore not be used,
substituted, although there are no data on the clinical effi- Despite encouraging reports adding ciprofloxacin or
cacy of this association in this indication. If the strain is rifampicin when dealing with multi-resistant strains pro-
intrinsically resistant to beta-lactams, vancomycin should vides no definite benefit'3'. However, recently, the addition
be used unless the strain is also resistant to this antibiotic. of chloramphenicol or tetracycline has been found to be
Table 5 Enterococcv. therapeutic options
(A) Cell-wall active agent antibiotics
(1) If Amp S and Vanco S, use Amp
(2) If Amp is used—consider continuous intravenous use
—look for beta-lactamase
(3) If beta-lactamase +, consider amoxicillin/clavulanate or imipenem
(4) If intrinsic beta-lactam R, consider Vanco
(5) If Vanco R, consider Teico
(6) If glycopeptides R, consider triple combination: Amp, Vanco, Genta
(B) Aminogylcoside (to be added to (A))
(1) If susceptible, synergistic effect is similar with Genta or Strepto
(2) If high genta R, test strepto
(3) If high levels of R to both, do not use them
(C) Other regimens
(1) Combination of cell-wall-active agents
(2) No definite benefit of adding Cipro or Rif
(3) Consider adding Chloro or Terra
(4) Test other antibiotics (e.g. pristinamycin)
Amp = ampicillin; Vanco = vancomycin; Teico = teicoplanin; Cipro =
ciproxin; Rif = rifampicin; Chloro = chloramphenicol; Genta = gentamicin;
Strepto = streptomycin; Tetra = tetracycline; S = sensitive; R = resistant.
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useful in some situations. It should be mentioned that
trimethoprim sulfamethoxazole appears to have an
inhibitory effect against many strains of enterococci when
tested in vitro. However, this agent is probably ineffective
in-vivo'31.
Despite some success with medical therapy alone in
endocarditis due to multi-resistant strains of enterococci,
surgical removal of the infected valve is often the only
curative treatment.
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